Parnell claims that its Nomovid is an easy-to-use and low-cost nasal spray product that can be rapidly commercialised over-the-counter to customers.
Parnell develops Nomovid nasal spray. (Credit: PIRO4D from Pixabay.)
US-based Parnell Pharmaceuticals has developed a topical nasal spray, dubbed Nomovid, for use as an antiviral treatment and prophylaxis against Covid-19.
The pharmaceutical company claimed that its Nomovid is an easy-to-use and low-cost nasal spray product that can be rapidly commercialised over-the-counter to customers.
Parnell Pharmaceuticals chairman and CEO Francis Parnell said: “An independent, outside laboratory has confirmed our findings and found it to be greater than 99.9% effective in vitro against the SARS-CoV-2 virus.
“Our product is based upon existing FDA approvals of the active ingredients for use in intravenous and inhalation formulations for other indications. Since the nose is the main route of entry into the body of SARS-CoV-2, we have prepared it in a nasal spray.”
Nomovid is said to work by breaking down the lipids inside viral envelope
The new nasal spray is designed based on a substance licensed by Parnell from New Mexico Tech University, which has the potential to act against drug-resistant bacteria and fungi such as MRSA and Candida auris.
Also, the drug is said to work by breaking down the lipids inside the viral envelope, and has been tested against the novel coronavirus, said the company.
Parnell Pharmaceuticals has applied with the Operation Warp Speed, a US government initiative, to receive funding and seeks the US Food and Drug Administration (FDA) Emergency Use Authorisation, which facilitates the manufacture and distribution of the product while the Phase 3 trials are underway.
Established in 1986, Parnell Pharmaceuticals is a privately held pharmaceutical company engaged in the development, manufacturing, and marketing of prescription and OTC drug products for maintenance and restoration of mucosal and skin integrity.
The company claimed that its products are natural-based and are patented for oral and nasal care, personal care, and anti-infective use, and are commercialised in North America and Europe.